Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Allogene Therapeutics Inc (ALLO)
NASDAQ:ALLO
RESEARCH TOOLSreports
Holding ALLO?
Track your performance easily
ALLO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.01 - $5.78
Previous Close$2.63
Volume1.10M
Average Volume (3M)2.57M
Market Cap
$556.24M
Enterprise Value$198.60M
Total Cash (Recent Filing)$444.63M
Total Debt (Recent Filing)$86.99M
Price to Earnings (P/E)―
Beta2.00
Next Earnings
Oct 31, 2024EPS Estimate
-$0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.61
Shares Outstanding209,111,516
10 Day Avg. Volume1,798,064
30 Day Avg. Volume2,574,798
Standard Deviation0.21
R-Squared0.04
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.08
Price to Sales (P/S)26487.46
Price to Cash Flow (P/CF)-2.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue9.46K
Enterprise Value/Gross Profit2.09K
Enterprise Value/Ebitda-0.74
Forecast
1Y Price Target
$9.95Price Target Upside278.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Allogene Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical ProgressAllogene announced 10 active sites enrolling patients for the pivotal ALPHA3 trial, in both the community and academic settings.
Licensing AgreementAllogene recently entered into a licensing agreement with Arbor Biotechnologies for the use of Arbor’s proprietary CRISPR gene-editing technology.
Market PotentialThe potential market for 1L consolidation therapy is estimated to be ~$5B currently.
Bears Say
Clinical TrialsThe delay of cema-cel CLL data into early-2025 could slightly disappoint investors.
Financial PerformanceAllogene reported collaboration revenue of $0.
Price TargetPrice target has been lowered to $14 from $35, as value has been removed for ALLO-715 in Multiple Myeloma, and ALLO-501 in late-line LBCL.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ALLO FAQ
What was Allogene Therapeutics Inc’s price range in the past 12 months?
Allogene Therapeutics Inc lowest stock price was $2.01 and its highest was $5.78 in the past 12 months.
What is Allogene Therapeutics Inc’s market cap?
Currently, no data Available
When is Allogene Therapeutics Inc’s upcoming earnings report date?
Allogene Therapeutics Inc’s upcoming earnings report date is Oct 31, 2024 which is in 61 days.
How were Allogene Therapeutics Inc’s earnings last quarter?
Allogene Therapeutics Inc released its earnings results on Aug 07, 2024. The company reported -$0.35 earnings per share for the quarter, the consensus estimate of -$0.35 by $0.
Is Allogene Therapeutics Inc overvalued?
According to Wall Street analysts Allogene Therapeutics Inc’s price is currently Undervalued.
Does Allogene Therapeutics Inc pay dividends?
Allogene Therapeutics Inc does not currently pay dividends.
What is Allogene Therapeutics Inc’s EPS estimate?
Allogene Therapeutics Inc’s EPS estimate is -$0.33.
How many shares outstanding does Allogene Therapeutics Inc have?
Allogene Therapeutics Inc has 209,111,510 shares outstanding.
What happened to Allogene Therapeutics Inc’s price movement after its last earnings report?
Allogene Therapeutics Inc reported an EPS of -$0.35 in its last earnings report, expectations of -$0.35. Following the earnings report the stock price went down -4.453%.
Which hedge fund is a major shareholder of Allogene Therapeutics Inc?
Among the largest hedge funds holding Allogene Therapeutics Inc’s share is PRIMECAP Management Co. It holds Allogene Therapeutics Inc’s shares valued at 13M.
---
Allogene Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.95 (278.33% Upside)
$9.95 (278.33% Upside)
Blogger Sentiment
Neutral
ALLO Sentiment 50%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 5.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $26.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.7%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.58%
12-Months-Change
Fundamentals
Return on Equity
-48.94%
Trailing 12-Months
Asset Growth
-16.10%
Trailing 12-Months
Company Description
Allogene Therapeutics Inc
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
---
ALLO Earnings Call
Q2 2024
0:00 / 0:00
---
ALLO Stock 12 Month Forecast
Average Price Target
$9.95
▲(278.33% Upside)
Technical Analysis
Best Analysts Covering ALLO
1 Year
1 Year Success Rate
5/18 ratings generated profit
1 Year Average Return
-20.73%
reiterated a buy rating 19 days ago
Copying John Newman's trades and holding each position for 1 Year would result in 27.78% of your transactions generating a profit, with an average return of -20.73% per trade.
---